Sergio Panay Serra

2.3K posts

Sergio Panay Serra banner
Sergio Panay Serra

Sergio Panay Serra

@DrSeps

Medical Oncologist. GU & Brain tumors

Metropolitana de Santiago, Chi Katılım Aralık 2010
0 Takip Edilen0 Takipçiler
Sergio Panay Serra retweetledi
Diego A. Díaz-García
Diego A. Díaz-García@diegoadiazg·
🫁 RELAY+ final OS. Ramucirumab + gefitinib in 1L EGFR-mutant metastatic NSCLC achieved a median OS of 47.4 months with a 3-year OS of 61.8%. High post-progression T790M rate (81%) supports preserved sequencing. Safety aligned with VEGFR inhibition. 📖 @JTOonline DOI 👉🏻 doi.org/10.1016/j.jtoc… #CánCare #NSCLC #EGFR #ThoracicOncology
Diego A. Díaz-García tweet mediaDiego A. Díaz-García tweet mediaDiego A. Díaz-García tweet media
English
2
8
53
3.3K
Sergio Panay Serra retweetledi
Arndt Vogel
Arndt Vogel@ArndtVogel·
Circulating tumor DNA as a biomarker in early phase clinical trials @Cancer_Cell doi.org/10.1016/j.ccel… 👉Review on current applications & future opportunities for ctDNA as a multi-utility biomarker in early phase clinical trials @myESMO
Arndt Vogel tweet media
English
0
28
64
8.9K
Sergio Panay Serra retweetledi
JAMA
JAMA@JAMA_current·
✅ Editor’s Choice: This Review summarizes the epidemiology, clinical presentation, pathophysiology, and management of renal cell #carcinoma (RCC). In 2023, there were an estimated 81 800 newly diagnosed cases of RCC in the US. 💾 Save this Review for your citations: ja.ma/3YrE58s
JAMA tweet media
English
2
121
358
45.4K
Sergio Panay Serra retweetledi
Abhijit Das, MD
Abhijit Das, MD@AbhijitSurgPath·
Prostate cancer: Gleason grading (Basic facts for residents)
Abhijit Das, MD tweet media
English
4
157
508
27.8K
Sergio Panay Serra retweetledi
NEJM
NEJM@NEJM·
A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2. Learn more in the Clinical Implications of Basic Research article “Understanding How Aspirin Prevents Metastasis” by Ruth E. Langley, MB, BS, PhD, and John Burn, MD, from University College London and @uniofnewcastle: nej.md/4pTzyaw
NEJM tweet media
English
7
246
849
67.4K
Sergio Panay Serra retweetledi
Oncology Brothers
Oncology Brothers@OncBrothers·
We have seen a few updates on PI3K I at #SABCS25! Here is the table we’ve used (common AEs, HbA1C inclusion, & dose⬇️) during our discussion on #Inavolisib, #Capivasertib, and #Alpelisib in HR+ mBC w/ @Neil_Iyengar & #DrGallagher #OncTwitter #MedTwitter @OncoAlert @OncUpdates
Oncology Brothers tweet media
Oncology Brothers@OncBrothers

ToxCheck: AEs for PI3K inhibitors & how to manage them when treating HR+ breast cancer w/ @Neil_Iyengar & #DrGallagher ✅ Inavolisib ✅ Capivasertib ✅ Alpelisib Full 🗣️: ⭐️ oncbrothers.com/pik3ca-toxchec… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates @OncoAlert

English
2
44
102
17.1K
Sergio Panay Serra retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
Key messages: - reasonable to consider in 1L, even after prior adjuvant CDK4/6i (if at least 1 year TFI) - benefit beyond 1L unknown — avoid - exclude (pre)diabetic patients - monitor closely fasting blood glucose - consider prophylactic metformin, cetirizine, steroid mouth wash
Paolo Tarantino tweet media
Paolo Tarantino@PTarantinoMD

When used in the right patients, the inavo/palbo/fulvestrant triplet dramatically prolongs PFS and OS. Yet, it comes with relevant toxicities. @DFCI_BreastOnc held consensus meetings to develop management guidelines, led by @GuiNaderMarta. Read them here: physicianresources.dana-farber.org/flexpaper/trea…

English
2
23
69
12.1K
Sergio Panay Serra retweetledi
Mustafa Özdoğan, MD
Mustafa Özdoğan, MD@ozdogan_md·
New Evidence on ADT Duration in Prostate Cancer (JAMA Oncology, Nov 2025) A meta-analysis of 10,266 patients shows a clear message. Risk-based approach matters: • 1 intermediate risk factor → 0 months • ≥2 risk factors → ~6 months • High-risk → ~12 months • Very high-risk → individualize This study challenges the old “longer is better” dogma and supports personalized ADT duration rather than fixed timelines. 🔗 jamanetwork.com/journals/jamao…
Mustafa Özdoğan, MD tweet media
English
1
53
130
10.1K
Sergio Panay Serra retweetledi
Hope Rugo
Hope Rugo@hoperugo·
Nice job with complex data but I don’t think we know yet when TDM1 is good enough. Perhaps for very small residual disease as you suggest. How to determine TDXd use and what to do if RD after DB11?
Pablo Mando@PabloMando

HER eBC management is improving survival but more complex. Here is a proposed algorithm with new advances post @myESMO #ESMO25 What do you think? What would you change? @matteolambe @PTarantinoMD @E_de_Azambuja @stolaney1 @Rodrosb @ElisaAgostinett @ErikaHamilton9 @hoperugo

English
2
22
89
14.2K
Sergio Panay Serra retweetledi
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
💫🌟📢 Long-term evidence speaks loud:🌟💫 🧬 The 23-year follow-up of the ERSPC trial confirms that PSA-based screening reduces #ProstateCancer mortality by 13%, with 1 death prevented per 456 men screened. ⚖️ Although diagnosis rates ↑, the benefit–harm balance improves over time, supporting risk-adapted screening approaches. 🔗 nejm.org/doi/full/10.10… @MoniqueRoobol @IvodeVos @ArnauldVillers @PoinasG @auvinen_anssi @OncoAlert @Silke_Gillessen @AOmlin #GUcancer #UroOncology
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano

European Study of Prostate Cancer Screening — 23-Year Follow-up nejm.org/doi/full/10.10… The 23-year follow-up of the European Randomized Study of Screening for #ProstateCancer (ERSPC) confirms that PSA-based screening yields a sustained reduction in prostate cancer mortality. Among more than 160,000 men aged 55–69 years across eight European countries, PSA screening📉 lowered prostate cancer deaths by 13% compared with no screening, with one death prevented for every 456 men invited to screening. Although screening increased 📈prostate cancer diagnoses by about 30%, the long-term data show an improved balance between benefits and harms compared to earlier analyses. The findings underscore that while PSA testing reduces mortality, future screening programs should adopt individualized, risk-based strategies to limit overdiagnosis and overtreatment. @MoniqueRoobol @IvodeVos @ArnauldVillers @PoinasG @auvinen_anssi @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

English
3
10
36
9K
Sergio Panay Serra retweetledi
Oncology Brothers
Oncology Brothers@OncBrothers·
Updated data on combination options seen at #ESMO25 for metastatic non-small cell lung cancer w/ EGFR mutated disease. Stuck w/ cross trial comparisons for now! We touched on this data and our options 👇👇 with @lungoncdoc! @EGFRSummit #OncTwitter #lcsm @OncoAlert @OncUpdates
Oncology Brothers tweet media
Oncology Brothers@OncBrothers

In our “Challenging Cases” discussion on metastatic NSCLC mEGFR w/ @lungoncdoc we touch on: ✅ Rx options ✅ AE management ✅ Sequencing Full discussion: ⭐️ Oncbrothers.com/egfr-cases-2025 ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter @OncUpdates

English
2
31
78
13.7K
Sergio Panay Serra retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
#ESMO25 Low-dose pembrolizumab in TNBC 🇮🇳 📌 Phase II RCT: neoadj ddAC → paclitaxel ± pembro 50 mg q6w × 3 🔹 pCR: 53.8 % vs 40.5 % (+13.3 %; p = 0.047) 💬 Despite ~10-fold lower IO exposure, the pCR delta (~13%) mirrors KN-522. The lower pCR in the control arm likely reflects the absence of carboplatin, underscoring the contribution of platinum to baseline efficacy in KN-522. May represent a feasible low-cost IO option in resource-limited settings. 🧩 Diff KN-522: – Chemo: ddAC → paclitaxel (no carbo) vs paclitaxel + carboplatin → AC/EC – Pembro dose: 50 mg q6w × 3 vs 200 mg q3w × 8 – pCR gain: +13.3 % vs +13.6 %
Yakup Ergün tweet media
English
3
27
94
32.3K
Sergio Panay Serra retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
ESMO HANDBOOK OF CANCER GENETICS AND GENOMICS #ESMO25 List of Actionable Genes and the FDA-approved Molecularly Matched Drugs👇
Yakup Ergün tweet media
English
5
123
322
34.1K
Sergio Panay Serra retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
Unresectable stage III non-small-cell lung cancer: state of the art and challenges Great review👇 nature.com/articles/s4157…
Yakup Ergün tweet mediaYakup Ergün tweet media
English
2
41
124
7.8K

Keşfet

@JTOonline @Cancer_Cell @myESMO @CCR_AACR @AACR @OncoAlert @uniofnewcastle @Neil_Iyengar